• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Remittance of primary cutaneous CD30 lymphoproliferative disorder in a patient on adalimumab.

作者信息

Ottevanger Rosanne, Melchers Rutger C, Quint Koen D

机构信息

Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

JAAD Case Rep. 2022 Feb 10;22:34-37. doi: 10.1016/j.jdcr.2022.02.003. eCollection 2022 Apr.

DOI:10.1016/j.jdcr.2022.02.003
PMID:35274033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8904182/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/af7ad2057fbb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/a48c99288618/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/f8cce8fd4cb9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/af7ad2057fbb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/a48c99288618/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/f8cce8fd4cb9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8eb/8904182/af7ad2057fbb/gr3.jpg

相似文献

1
Remittance of primary cutaneous CD30 lymphoproliferative disorder in a patient on adalimumab.接受阿达木单抗治疗的一名原发性皮肤CD30淋巴细胞增殖性疾病患者病情缓解。
JAAD Case Rep. 2022 Feb 10;22:34-37. doi: 10.1016/j.jdcr.2022.02.003. eCollection 2022 Apr.
2
MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.MUM1在皮肤CD30+淋巴增殖性疾病中的表达：鉴别淋巴瘤样丘疹病和原发性皮肤间变性大细胞淋巴瘤的重要工具。
Br J Dermatol. 2008 Jun;158(6):1280-7. doi: 10.1111/j.1365-2133.2008.08566.x. Epub 2008 Apr 10.
3
Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.皮肤CD30阳性淋巴增殖性疾病的基因组分析
JID Innov. 2021 Nov 15;2(1):100068. doi: 10.1016/j.xjidi.2021.100068. eCollection 2022 Jan.
4
CD30-Positive Lymphoproliferative Disorders.CD30 阳性淋巴增殖性疾病
Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.
5
Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases.伴有共存上皮性肿瘤的皮肤CD30阳性淋巴增殖性疾病：两例报告
Australas J Dermatol. 2015 Nov;56(4):e83-7. doi: 10.1111/ajd.12180. Epub 2014 Oct 21.
6
Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.在累及皮肤的CD30阳性淋巴增殖性疾病中，由FADD介导的死亡受体凋亡信号传导。
Am J Surg Pathol. 2005 Apr;29(4):452-9. doi: 10.1097/01.pas.0000155154.46434.93.
7
Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.一名克罗恩病患者患B型淋巴瘤样丘疹病，接受肿瘤坏死因子-α抑制剂英夫利昔单抗和阿达木单抗治疗。
Acta Dermatovenerol Croat. 2019 Sep;27(3):202-204.
8
The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.皮肤中CD30+ T细胞淋巴增殖性疾病的谱系
Chin Clin Oncol. 2019 Feb;8(1):3. doi: 10.21037/cco.2018.12.03. Epub 2019 Jan 9.
9
Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.Fascin在CD30阳性皮肤淋巴增殖性疾病中的表达。
J Cutan Pathol. 2002 May;29(5):295-300. doi: 10.1034/j.1600-0560.2002.290507.x.
10
The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.t(2;5)染色体易位并非原发性皮肤CD30+淋巴增殖性疾病的常见特征：与淋巴结起源的间变性大细胞淋巴瘤的比较。
Blood. 1996 Apr 15;87(8):3437-41.

本文引用的文献

1
Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.一名克罗恩病患者患B型淋巴瘤样丘疹病，接受肿瘤坏死因子-α抑制剂英夫利昔单抗和阿达木单抗治疗。
Acta Dermatovenerol Croat. 2019 Sep;27(3):202-204.
2
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.2018 年版 WHO-EORTC 原发性皮肤淋巴瘤分类。
Blood. 2019 Apr 18;133(16):1703-1714. doi: 10.1182/blood-2018-11-881268. Epub 2019 Jan 11.
3
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.
抗肿瘤坏死因子 α 制剂治疗炎症性肠病患者的淋巴瘤风险：系统评价和荟萃分析。
J Crohns Colitis. 2018 Aug 29;12(9):1042-1052. doi: 10.1093/ecco-jcc/jjy065.
4
Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases.慢性胃肠道和肝脏疾病的高需求、高费用患者住院的年度负担和费用。
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1284-1292.e30. doi: 10.1016/j.cgh.2018.02.015. Epub 2018 Feb 21.
5
Changing epidemiological trends of inflammatory bowel disease in Asia.亚洲炎症性肠病流行病学趋势的变化
Intest Res. 2016 Apr;14(2):111-9. doi: 10.5217/ir.2016.14.2.111. Epub 2016 Apr 27.
6
Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis.阿达木单抗治疗幼年特发性关节炎后发生淋巴瘤样丘疹病。
Dermatology. 2012;225(3):259-63. doi: 10.1159/000345104. Epub 2012 Dec 13.
7
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.阿达木单抗：来自全球类风湿关节炎、幼年特发性关节炎、强直性脊柱炎、银屑病关节炎、银屑病和克罗恩病临床试验的 23458 例患者的长期安全性。
Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5.
8
Brentuximab Vedotin (SGN-35).本妥昔单抗维迪昔（SGN-35）。
Clin Cancer Res. 2011 Oct 15;17(20):6428-36. doi: 10.1158/1078-0432.CCR-11-0488.
9
Mycosis fungoides-associated follicular mucinosis under adalimumab.阿达木单抗治疗下蕈样肉芽肿相关毛囊黏蛋白病
Br J Dermatol. 2005 Jul;153(1):207-8. doi: 10.1111/j.1365-2133.2005.06686.x.
10
WHO-EORTC classification for cutaneous lymphomas.世界卫生组织-欧洲癌症研究与治疗组织皮肤淋巴瘤分类
Blood. 2005 May 15;105(10):3768-85. doi: 10.1182/blood-2004-09-3502. Epub 2005 Feb 3.